4-[(2-methyl-4-quinolinyl)methoxy]-aniline bis HCl salt

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 4-[(2-methyl-4-quinolinyl)methoxy]-aniline bis HCl salt
• 英文别名: 4-(2-Methyl-quinolin-4-ylmethoxy)-phenylamine hydrochloride；4-[(2-methylquinolin-4-yl)methoxy]aniline;hydrochloride
• 化学式: C₁₇H₁₆N₂O*2ClH
• 分子量: 337.249
• InChiKey: JGWRZEYAYBQIAD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.13
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  48.1
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-[(2-methyl-4-quinolinyl)methoxy]-aniline bis HCl salt 在 碳酸氢钠 、 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 二甲基亚砜 为溶剂， 以8%的产率得到(cis,trans)-N-{4-[(2-methyl-4-quinolinyl)methoxy]phenyl}-2,4-dioxo-1,3-diazaspiro[4.4]nonane-6-carboxamide
  参考文献：
  名称：

  Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme (TACE)

  摘要：

  本申请描述了具有以下式(I)的新型咪唑啉衍生物：1或其药用可接受的盐或前药形式，其中A、B、R1、R2、R3、R4、R5、R6、R7、R11和n在本说明书中有定义，这些衍生物可用作基质金属蛋白酶（MMP）、TNF-α转化酶（TACE）、聚集素酶的抑制剂，或其组合。

  公开号：

  US20030130273A1
• 作为产物：
  描述：

  [4-(2-methylquinolin-4-ylmethoxy)phenyl]-carbamic acid tert-butyl ester 在 盐酸 作用下， 以 1,4-二氧六环 、 乙酸乙酯 为溶剂， 反应 3.0h， 以1.3 g的产率得到4-[(2-methyl-4-quinolinyl)methoxy]-aniline bis HCl salt
  参考文献：
  名称：

  AZA SPIRO ALKANE DERIVATIVES AS INHIBITORS OF METALLPROTEASES

  摘要：

  公开号：

  EP1622569B1

文献信息

• Barbituric acid derivatives as inhibitors of TNF-alpha converting enzyme (TACE) and/or matrix metalloproteinases
  申请人：——

  公开号：US20030229084A1

  公开（公告）日：2003-12-11

  The present application describes novel barbituric acid derivatives of formula I: 1 or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, B, L, R 1 , R 2 , R 3 , R 4 , R 5 , n, W, U, X, Y, Z, U a , X a , Y a , and Z a are defined in the present specification, which are useful as TNF-&agr; converting enzyme (TACE) and matrix metalloproteinases (MMP) inhibitors.

  本申请描述了式I的新型巴比妥酸衍生物： 1 或其药用可接受的盐或前药形式，其中A、B、L、R 1 、R 2 、R 3 、R 4 、R 5 、n、W、U、X、Y、Z、U a 、X a 、Y a 和Z a 在本规范中定义，这些衍生物可用作TNF-α转化酶（TACE）和基质金属蛋白酶（MMP）抑制剂。
• [EN] SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES<br/>[FR] INHIBITEURS DE METALLOPROTEASES MATRICES A BASE D'HYDROXAMATES CYCLIQUES SUBSTITUES
  申请人：INCYTE CORP

  公开号：WO2005037826A1

  公开（公告）日：2005-04-28

  The present invention provides compounds of the formula I: its enantiomers, diastereomers, racemic mixtures thereof, prodrugs, crystalline forms, non-crystalline forms, amorphous forms thereof, solvates thereof, metabolites thereof, and pharmaceutically acceptable salts, wherein the ring A substituent groups are fully defined in the following disclosure. The compounds of formula I are inhibitors of metalloproteases such as matrix metalloproteases and sheddases, and are useful in treating diseases such as rheumatoid arthritis, psoriasis, neoplastic diseases, allergies and all those diseases wherein inhibition of MMPs is desirable.

  本发明提供了公式I的化合物：其对映异构体，二对映异构体，混合物，前药，结晶形式，非晶形式，无定形形式，溶剂化物，代谢物和药学上可接受的盐，其中环A取代基在以下披露中被完全定义。公式I的化合物是金属蛋白酶抑制剂，如基质金属蛋白酶和剪切酶的抑制剂，并且在治疗风湿性关节炎，牛皮癣，肿瘤性疾病，过敏和所有需要MMPs抑制的疾病中有用。
• Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases
  申请人：Li Yun-Long

  公开号：US20050113344A1

  公开（公告）日：2005-05-26

  The present invention provides compounds of the formula I: its enantiomers, diastereomers, racemic mixtures thereof, prodrugs, crystalline forms, non-crystalline forms, amorphous forms thereof, solvates thereof, metabolites thereof, and pharmaceutically acceptable salts, wherein the ring A substituent groups are fully defined in the following disclosure. The compounds of formula I are inhibitors of metalloproteases such as matrix metalloproteases and sheddases, and are useful in treating diseases such as rheumatoid arthritis, psoriasis, neoplastic diseases, allergies and all those diseases wherein inhibition of MMPs is desirable.

  本发明提供了I式化合物：其对映体、非对映异构体、混合物、前药、晶体形态、非晶体形态、无定形形态、溶剂化物、代谢物和药学上可接受的盐，其中环A的取代基在以下披露中被充分定义。I式化合物是金属蛋白酶抑制剂，例如基质金属蛋白酶和脱落素酶，并且在治疗类风湿性关节炎、牛皮癣、肿瘤性疾病、过敏和所有需要抑制MMPs的疾病中有用。
• BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-alpha CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES
  申请人：Duan Jingwu

  公开号：US20070167451A1

  公开（公告）日：2007-07-19

  The present application describes novel barbituric acid derivatives of formula I: or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, B, L, R 1 , R 2 , R 3 , R 4 , R 5 , n, W, U, X, Y, Z, U a , X a , Y a , and Z a are defined in the present specification, which are useful as TNF-α converting enzyme (TACE) and matrix metalloproteinases (MMP) inhibitors.

  本申请描述了新型的巴比妥酸衍生物式I：或其药物可接受的盐或前药形式，其中A、B、L、R1、R2、R3、R4、R5、n、W、U、X、Y、Z、Ua、Xa、Ya和Za在本说明书中有定义，它们可用作TNF-α转化酶（TACE）和基质金属蛋白酶（MMP）抑制剂。
• Substituted cyclic hydroxamates as lnhibitors of matrix metalloproteinases
  申请人：Li Yun Long

  公开号：US20080167288A1

  公开（公告）日：2008-07-10

  The present invention provides compounds of the formula: its enantiomers, diastereomers, racemic mixtures thereof, prodrugs, crystalline forms, non-crystalline forms, amorphous forms thereof, solvates thereof, metabolites thereof, and pharmaceutically acceptable salts, wherein the ring A substituent groups are fully defined in the following disclosure. The compounds of formula are inhibitors of metalloproteases such as matrix metalloproteases and sheddases, and are useful in treating diseases such as rheumatoid arthritis, psoriasis, neoplastic diseases, allergies and all those diseases wherein inhibition of MMPs is desirable.

  本发明提供了公式的化合物：其对映异构体、非对映异构体、混合物、前药、晶体形式、非晶体形式、无定形形式、溶剂化物、代谢物和药学上可接受的盐，其中环A的取代基在下面的披露中被完全定义。公式化合物是金属蛋白酶抑制剂，如基质金属蛋白酶和脱落酶，可用于治疗风湿性关节炎、银屑病、肿瘤性疾病、过敏和所有需要抑制MMP的疾病。